Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30

Sylvia Lee-Huang, Philip L. Huang, Yongtao Sun, Hao Chia Chen, Hsiang Fu Kung, Paul L. Huang, William J Murphy

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, the mice developed extensive metastases and all mice succumbed to tumor by day 46. Treatment of the human breast cancer bearing SCID mice with GAP31 or MAP30 at 10 μg/injection EOD for 10 injections resulted in significant increases in survival, with 20-25% of the mice remaining tumor free for 96 days. Thus, antitumor agents GAP31 and MAP30 are effective against human breast cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.

Original languageEnglish (US)
Pages (from-to)653-659
Number of pages7
JournalAnticancer Research
Volume20
Issue number2 A
StatePublished - 2000
Externally publishedYes

Fingerprint

Momordica
Heterografts
Breast Neoplasms
Neoplasms
Proteins
SCID Mice
Suregada
Momordica charantia
erbB-2 Genes
Injections
Neoplasm Antigens
Therapeutic Uses
Medicinal Plants
Antineoplastic Agents
Estrogens
Cell Proliferation
Neoplasm Metastasis
Survival

Keywords

  • Anti-tumor
  • Breast carcinoma
  • In vitro
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lee-Huang, S., Huang, P. L., Sun, Y., Chen, H. C., Kung, H. F., Huang, P. L., & Murphy, W. J. (2000). Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Research, 20(2 A), 653-659.

Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. / Lee-Huang, Sylvia; Huang, Philip L.; Sun, Yongtao; Chen, Hao Chia; Kung, Hsiang Fu; Huang, Paul L.; Murphy, William J.

In: Anticancer Research, Vol. 20, No. 2 A, 2000, p. 653-659.

Research output: Contribution to journalArticle

Lee-Huang, S, Huang, PL, Sun, Y, Chen, HC, Kung, HF, Huang, PL & Murphy, WJ 2000, 'Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30', Anticancer Research, vol. 20, no. 2 A, pp. 653-659.
Lee-Huang S, Huang PL, Sun Y, Chen HC, Kung HF, Huang PL et al. Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Research. 2000;20(2 A):653-659.
Lee-Huang, Sylvia ; Huang, Philip L. ; Sun, Yongtao ; Chen, Hao Chia ; Kung, Hsiang Fu ; Huang, Paul L. ; Murphy, William J. / Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. In: Anticancer Research. 2000 ; Vol. 20, No. 2 A. pp. 653-659.
@article{b83622867684486c8e9c229480e75f7b,
title = "Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30",
abstract = "GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, the mice developed extensive metastases and all mice succumbed to tumor by day 46. Treatment of the human breast cancer bearing SCID mice with GAP31 or MAP30 at 10 μg/injection EOD for 10 injections resulted in significant increases in survival, with 20-25{\%} of the mice remaining tumor free for 96 days. Thus, antitumor agents GAP31 and MAP30 are effective against human breast cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.",
keywords = "Anti-tumor, Breast carcinoma, In vitro, Xenograft",
author = "Sylvia Lee-Huang and Huang, {Philip L.} and Yongtao Sun and Chen, {Hao Chia} and Kung, {Hsiang Fu} and Huang, {Paul L.} and Murphy, {William J}",
year = "2000",
language = "English (US)",
volume = "20",
pages = "653--659",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 A",

}

TY - JOUR

T1 - Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30

AU - Lee-Huang, Sylvia

AU - Huang, Philip L.

AU - Sun, Yongtao

AU - Chen, Hao Chia

AU - Kung, Hsiang Fu

AU - Huang, Paul L.

AU - Murphy, William J

PY - 2000

Y1 - 2000

N2 - GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, the mice developed extensive metastases and all mice succumbed to tumor by day 46. Treatment of the human breast cancer bearing SCID mice with GAP31 or MAP30 at 10 μg/injection EOD for 10 injections resulted in significant increases in survival, with 20-25% of the mice remaining tumor free for 96 days. Thus, antitumor agents GAP31 and MAP30 are effective against human breast cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.

AB - GAP31 (Gelonium protein of 31 kDa) and MAP30 (Momordica protein of 30 kDa) are agents isolated from the medicinal plants Gelonium multiflorum and Momordica charantia, respectively. The current study was conducted to investigate the efficacy of GAP31 and MAP30 on estrogen-independent and highly metastatic human breast tumor MDA-MB-231 both in vitro and in vivo. The effect of these agents on the expression of breast tumor antigen HER2 (also known as neu or as c-erbB 2) was also examined. Treatment of MDA-MB-231 breast cancer cells with GAP31 and MAP30 resulted in inhibition of cancer cell proliferation as well as inhibition of the expression of HER2 gene in vitro. When MDA-MB-231 human breast cancer cells were transferred into SCID mice, the mice developed extensive metastases and all mice succumbed to tumor by day 46. Treatment of the human breast cancer bearing SCID mice with GAP31 or MAP30 at 10 μg/injection EOD for 10 injections resulted in significant increases in survival, with 20-25% of the mice remaining tumor free for 96 days. Thus, antitumor agents GAP31 and MAP30 are effective against human breast cancer MDA-MB-231 in vitro and in vivo. There agents may therefore be of potential therapeutic use against breast carcinomas.

KW - Anti-tumor

KW - Breast carcinoma

KW - In vitro

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=0034090956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034090956&partnerID=8YFLogxK

M3 - Article

C2 - 10810336

AN - SCOPUS:0034090956

VL - 20

SP - 653

EP - 659

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 A

ER -